不同疗效的非霍奇金淋巴瘤血清蛋白质质谱分析

目的分析正常组、非霍奇金淋巴瘤(NHL)化疗6周期后完全缓解(CR)及NHL化疗6周期后未完全缓解或缓解后3月内复发患者的血清差异表达蛋白质,为筛选和建立NHL临床疗效监测及预后评估的血清学指标提供理论依据。方法采用表面增强激光解析离子化飞行时间质谱(SELDI-TOFMS)技术,应用铜离子结合芯片(IMAC-Cu)以及配套软件,对35例正常组,35例NHL化疗6周期后CR患者组,35例NHL化疗6周期后未完全缓解或缓解后3月内复发患者组的血清差异表达蛋白质进行检测分析,构建决策树分类模型。结果(1)正常组和NHL化疗6周期后CR患者组共有6种差异表达蛋白质有分类意义,质荷比分别为M8778.14u、M8887.83u、M8529.39u、M9076.76u、M9242.75u、M5848.92u,M/Z为M5848.2u的一种蛋白质被软件系统选取建立决策树分类模型,灵敏度和特异性分别为88.57%和100%;(2)正常组和NHL化疗6周期后未CR或缓解后3月内复发患者组共有6种差异表达蛋白质有分类意义,质荷比分别为M8890.26u、M5853.70u、M5444.38u、M8784.58u、M6354.226 u、M8 539. 28 u ,其中M/ Z 为M5 444. 38 u 的一种蛋白质被软件系统选取建立决策树分类模型,灵敏度和特异性分别为85. 71 %和100 %;(3) NHL 化疗6 周期后CR 患者和NHL 化疗6 周期后未CR 或缓解后3 月内复发患者组共有6 种差异表达蛋白质有分类意义, 质荷比分别为M6 436. 04 u、M5 509. 43 u、M6 633. 93 u、M14 047. 6 u、M7 769. 91 u、M6 009. 63 u ,其中M/ Z 为M6 436. 04 u 的一种蛋白质被软件系统选取建立决策树分类模型,灵敏度和特异性分别为77. 14 %和100 %。结论　有分类意义的18 种差异表达蛋白质有可能成为N HL临床疗效监测及指导临床治疗的一组分子学指标。

Analysis of Serum Proteome Profiles of Subjects with Complete Response and Refractori-ness Non-hodgkin's Lymphoma

Objective Through the analysis of the serum differentially expressed proteins of the health adults, the Non-Hodgkin s Lymphoma(NHL) with complete response(CR) after 6 cycles chemotherapy and the NHL without CR or recrudescence in 3 months after 6 cycles chemotherapy, the research is endeavored to provide a theoretical foundation for the serological index in screening, establishing the clinical therapeutic effect monitoring and prognosis evaluation of NHL. Methods The research applied SELDI-TOF MS and IMAC-u chip to detection the differentially expressed serum proteins of the health adult s ,the N HL patient s with CR af ter six cycles chemotherapy and the N HL patient s with no remission or recrudescence in three months af ter six cycles chemotherapy who are 35 cases respectively ,and to constitutethe decision t ree classification model. Results 　(1) Between the health adult s and the NHL with CR af ter6 cycles chemotherapy , six kinds of differentially expressed proteins were found to have the categorizingsignificance , whose M/ Z are M8 778. 14 u , M8 887. 83 u , M8 529. 39 u ,M9 076. 76 u , M9 242. 75 u ,M5 848. 92 u respectively , and the protein with the M/ Z M5 848. 92 u was selected by the sof tware system to establish the decision t ree classification model with the sensitivity of 88. 57 % and the specificity of100 %. (2) Between the health adult s and the NHL without CR or recrudescence in 3 months af ter 6 cycles chemotherapy , six kinds of differentially expressed proteins were found to have the categorizing significance , whose M/ Z are M8 890. 26 u , M5 853. 70 u , M5 444. 38 u , M8 784. 58 u , M6 354. 26 u ,M8 539. 28 u respectively , and the protein with the M/ Z M 5 444. 38 u was selected by the sof tware system to establish the decision t ree classification model with the sensitivity of 85. 71 % , and the specificityof 100 %. (3) Between the NHL with CR af ter 6 cycles chemotherapy and the N HL without CR or recrudescence in 3 months after 6 cycles chemotherapy , six kinds of differentially expressed proteins werefound to have the categorizing significance , whose M/ Z are M6 436. 04 u ,M5 509. 43 u ,M6 633. 93 u ,M14 047. 6 u ,M7 769. 91 u ,M6 009. 63 u respectively , and the protein with the M/ Z M6 436. 04 u wasselected by the sof tware system to establish the decision t ree classification model with the sensitivity of77. 14 % , and the specificity of 100 %. Conclusion 　These 18 differentially expressed proteins which holdcategorizing significance might potentially be a group of biomarkers for monitoring clinical effect and directing clinical t reatment of N HL.